Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Hold” from Brokerages

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have earned an average rating of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $11.00.

NBTX has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. acquired a new stake in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

Nanobiotix Price Performance

Shares of NASDAQ:NBTX opened at $22.13 on Friday. Nanobiotix has a 52 week low of $2.82 and a 52 week high of $30.35. The company’s 50 day moving average is $21.50 and its two-hundred day moving average is $13.26.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.